Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Ticker SymbolPCRX
Company namePacira Biosciences Inc
IPO dateFeb 03, 2011
CEOMr. Frank D. Lee
Number of employees790
Security typeOrdinary Share
Fiscal year-endFeb 03
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94005
Phone16502428052
Websitehttps://www.pacira.com/
Ticker SymbolPCRX
IPO dateFeb 03, 2011
CEOMr. Frank D. Lee
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data